Pharmacovigilance services encompass the comprehensive monitoring, detection, evaluation, and prevention of adverse effects or drug-related issues associated with the utilization of medications and medical products. This vital process ensures the safety of drugs and medical devices throughout their entire lifecycle, from development to post-marketing surveillance.

BioGreen’s pharmacovigilance offerings are bolstered by a team of highly trained and experienced professionals, complemented by regulatory, GMP, and design experts, offering a comprehensive suite of support services. Adopting a risk-based approach, the team efficiently allocates resources to address critical product quality and patient safety concerns.

Our consultants expertly navigate regulatory landscapes, assisting clients in establishing compliant systems for both existing and new facilities manufacturing pharmaceuticals, medical devices, or biologics.

When hands-on support is required for pharmacovigilance programs or systems, BioGreen provides a pool of capable and professional contractors to choose from.

Navigating the complexities of selecting the ideal partner for pharmacovigilance, medical information, and device vigilance services in Australia and New Zealand necessitates careful consideration. Experience, quality, efficiency, and compliance are paramount, alongside adaptability to unique needs and regulatory requirements. Cultural alignment and compatibility are also crucial for a successful and enduring partnership.

Partner with BioGreen and experience our unwavering commitment to treating each client’s project as our top priority.

As defined by the World Health Organization (WHO), pharmacovigilance involves the scientific activities aimed at detecting, assessing, understanding, and preventing adverse effects and other medicine-related issues, ensuring drug and medical device safety from development to post-marketing.

Tailored approaches are essential for post-marketing pharmacovigilance programs due to varying regulatory requirements. Collaborations may necessitate safety data exchange agreements (SDEAs) or pharmacovigilance agreements (PVAs).

BioGreen, a leading Australian entity, prioritizes patient safety throughout the product lifecycle, offering a diverse range of pharmacovigilance and vigilance services to sponsors in Australia, New Zealand, and internationally.

Complementary Services:Medical Information, 
Device Vigilance, Product Quality Complaints, Consultation for Unapproved Medicine Systems, such as the Special Access Scheme and Clinical Trials

BioGreen, a leading authority in medical device vigilance and regulatory affairs, emphasizes the importance of comprehensive reporting as mandated by Australian regulations. BioGreen provides detailed guidance on vigilance reporting nuances, ensuring compliance and proactive communication with sponsors in the event of adverse event reporting. Our commitment to stringent reporting of adverse events and ‘near adverse events’ through the Medical Device Incident Reporting (MDIR) system underscores our dedication to patient safety.